Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats

Microvascular Research

Volumn 73, Issue 3, 2007, Pages 198-205

  Rigsby, Christine' S ^a   Pollock, David M ^a   Dorrance, Anne M ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Aldosterone; Arteriograph; Hypertension; Middle cerebral artery; SHRSP; Spironolactone; Vascular remodeling

Indexed keywords

SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIOGRAPHY; ARTERY DIAMETER; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL TONE; BRAIN BLOOD VESSEL; CONTROLLED STUDY; MALE; MEAN ARTERIAL PRESSURE; MIDDLE CEREBRAL ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; TELEMETRY; WISTAR KYOTO RAT;

ALDOSTERONE ANTAGONISTS; ANIMALS; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR CIRCULATION; COMPLIANCE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION; MALE; MIDDLE CEREBRAL ARTERY; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SEROTONIN; SPIRONOLACTONE; TELEMETRY; TIME FACTORS;

RATTUS;

EID: 34247160501     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2006.12.001     Document Type: Article

References (38)

1. Baumbach G.L., and Heistad D.D. Remodeling of cerebral arterioles in chronic hypertension. Hypertension 13 (1989) 968-972
2. Benetos A., Lacolley P., and Safar M.E. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 1152-1156
3. Brunner H.R., Laragh J.H., Baer L., Newton M.A., Goodwin F.T., Krakoff L.R., Bard R.H., and Buhler F.R. Essential hypertension: renin and aldosterone, heart attack and stroke. N. Engl. J. Med. 286 (1972) 441-449
4. Cipolla M.J., Lessov N., Clark W.M., and Haley Jr. E.C. Postischemic attenuation of cerebral artery reactivity is increased in the presence of tissue plasminogen activator. Stroke 31 (2000) 940-945
5. Cipolla M.J., Lessov N., Hammer E.S., and Curry A.B. Threshold duration of ischemia for myogenic tone in middle cerebral arteries: effect on vascular smooth muscle actin. Stroke 32 (2001) 1658-1664
6. Connell J.M.C., and Davies E. The new biology of aldosterone. J. Endocrinol. 186 (2005) 1-20
7. Connell J.M., Fraser R., MacKenzie S., and Davies E. Is altered adrenal steroid biosynthesis a key intermediate phenotype in hypertension?. Hypertension 41 (2003) 993-999
8. Coulson R.J., Chesler N.C., Vitullo L., and Cipolla M.J. Effects of ischemia and myogenic activity on active and passive mechanical properties of rat cerebral arteries. Am. J. Physiol.: Heart Circ. Physiol. 283 (2002) H2268-H2275
9. Coyle P. Dorsal cerebral collaterals of stroke-prone spontaneously hypertensive rats (SHRSP) and Wistar Kyoto rats (WKY). Anat. Rec. 218 (1987) 40-44
10. Coyle P., and Feng X. Risk area and infarct area relations in the hypertensive stroke-prone rat. Stroke 24 (1993) 705-709 (discussion 710)
11. Coyle P., and Heistad D.D. Blood flow through cerebral collateral vessels one month after middle cerebral artery occlusion. Stroke 18 (1987) 407-411
12. Coyle P., and Heistad D.D. Development of collaterals in the cerebral circulation. Blood Vessels 28 (1991) 183-189
13. Coyle P., and Jokelainen P.T. Differential outcome to middle cerebral artery occlusion in spontaneously hypertensive stroke-prone rats (SHRSP) and Wistar Kyoto (WKY) rats. Stroke 14 (1983) 605-617
14. Dorrance A.M., Osborn H., Grekin R., and Webb R.C. Aldosterone antagonism reduces cerebral infarct size in normotensive rats. J. Hypertens. 18 (2000) S84
15. Dorrance A.M., Osborn H.L., Grekin R., and Webb R.C. Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am. J. Physiol.: Regul., Integr. Comp. Physiol. 281 (2001) R944-R950
16. Dorrance A.M., Rupp N., Pollock D.M., Newman J.W., Hammock B.D., and Imig J.D. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 46 (2005) 842-848
17. Dorrance A.M., Rupp N.C., and Nogueira E.F. Mineralocorticoid receptor activation causes cerebral vessel remodeling and exacerbates the damage caused by cerebral ischemia. Hypertension 47 (2006) 590-595
18. Dorrance A.M., Pollock D.M., Romanko O.P., and Stepp D.W. A high potassium diet reduces infarct size and improves vascular structure in hypertensive rats. Am. J. Physiol.: Regul., Integr. Comp. Physiol. 292 (2007) R415-R422
19. Endemann D.H., Touyz R.M., Iglarz M., Savoia C., and Schiffrin E.L. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 43 (2004) 1252-1257
20. Funder J.W. Aldosterone, mineralocorticoid receptors and vascular inflammation. Mol. Cell. Endocrinol. 217 (2004) 263-269
21. Heagerty A.M., Aalkjaer C., Bund S.J., Korsgaard N., and Mulvany M.J. Small artery structure in hypertension. Dual processes of remodeling and growth. Hypertension 21 (1993) 391-397
22. Irvine R.J., White J., and Chan R. The influence of restraint on blood pressure in the rat. J. Pharmacol. Toxicol. Methods 38 (1997) 157-162
23. Izzard A.S., Graham D., Burnham M.P., Heerkens E.H., Dominiczak A.F., and Heagerty A.M. Myogenic and structural properties of cerebral arteries from the stroke-prone spontaneously hypertensive rat. Am. J. Physiol.: Heart Circ. Physiol. 285 (2003) H1489-H1494
24. Kannel W. On the cardiovascular hazards of hypertension. In: Onesti G., and Klint C.R. (Eds). Hypertension Determinants, Complications, and Intervention (1979), Grune and Stratton, New York 143-149
25. Longa E.Z., Weinstein P.R., Carlson S., and Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20 (1989) 84-91
26. MacLeod A.B., Vasdev S., and Smeda J.S. The role of blood pressure and aldosterone in the production of hemorrhagic stroke in captopril-treated hypertensive rats. Stroke 28 (1997) 1821-1829
27. Mulvany M.J., Baumbach G.L., Aalkjaer C., Heagerty A.M., Korsgaard N., Schiffrin E.L., and Heistad D.D. Vascular remodeling. Hypertension 28 (1996) 505-506
28. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., and Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N. Engl. J. Med. 341 (1999) 709-717
29. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., and Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348 (2003) 1309-1321
30. Rocha R., and Funder J.W. The pathophysiology of aldosterone in the cardiovascular system. Ann. N. Y. Acad. Sci. 970 (2002) 89-100
31. Rocha R., and Stier Jr. C.T. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol. Metab. 12 (2001) 308-314
32. Rocha R., Chander P.N., Khanna K., Zuckerman A., and Stier Jr. C.T. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31 (1998) 451-458
33. Sasser J.M., Pollock J.S., and Pollock D.M. Renal endothelin in chronic angiotensin II hypertension. Am. J. Physiol.: Regul., Integr. Comp. Physiol. 283 (2002) R243-R248
34. Schiffrin E.L., and Touyz R.M. From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am. J. Physiol.: Heart Circ. Physiol. 287 (2004) H435-H446
35. Struthers A.D., and MacDonald T.M. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc. Res. 61 (2004) 663-670
36. Thom T., Haase N., Rosamond W., Howard V.J., Rumsfeld J., Manolio T., Zheng Z.-J., Flegal K., O'Donnell C., Kittner S., Lloyd-Jones D., GoffJr D.C., Hong Y., Stroke Statistics S., Adams R., Friday G., Furie K., Gorelick P., Kissela B., Marler J., Meigs J., Roger V., Sidney S., Sorlie P., Steinberger J., Wasserthiel-Smoller S., Wilson M., and Wolf P. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113 (2006) e85-e151
37. Virdis A., Neves M.F., Amiri F., Viel E., Touyz R.M., and Schiffrin E.L. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40 (2002) 504-510
38. Yamori Y., Horie R., Handa H., Sato M., and Fukase M. Pathogenetic similarity of strokes in stroke-prone spontaneously hypertensive rats and humans. Stroke 7 (1976) 46-53